AC Immune announces interim safety, tolerability from Phase 1b/2 ABATE trial

AC Immune announced the first interim safety, tolerability and immunogenicity findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta vaccine ACI-24.060 in patients with prodromal Alzheimer’s disease, AD. ABATE will now be expanded, as planned, to include individuals with Down syndrome, DS, and to evaluate higher doses in Alzheimer’s patients. Early results from the first cohort of AD patients in ABATE showed that low dose ACI-24.060 could elicit an anti-Abeta antibody response as soon as week 6. The data show that ACI-24.060 vaccination has been safe and well tolerated to date. As a result, dosing in ABATE’s second, higher dose AD cohort has now begun and the trial is cleared to begin screening individuals with DS for part 2 of the study. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "We are delighted with the encouraging initial safety and immunogenicity findings for ACI-24.060 in ABATE reported today. We believe ACI-24.060’s successful development could provide patients with a novel therapeutic option offering numerous potential advantages in treatment, maintenance, and prevention settings. These early findings from ABATE represent an important step towards this goal, and we look forward to reporting more detailed data at a future conference."